## K:\ACOLLINS\LKS\9510\4THSID AJC94

DEB:HEW:AJC:kfd March 15, 1999



PATENT APPLICATION DOCKET NO.: LKS95-10

Suppl. IDS W/P

## ENT AND TRADEMARK OFFICE

Applicants:

Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, José Saldanha and Mary M.

**Bendig** 

Application No.:

08/700,737

Group Art Unit: 1644

Filed:

August 15, 1996

Examiner: E. Rabin

Title:

[]

(Filed after payment of issue fee)

Humanized Imműnoglobulin Reactive with α4β7 Integrin

Date: MARCH 15, 1999

EXPRESS MAIL LABEL NO. EL192626136US

## FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** Washington, D.C. 20231 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or [] (First/Second submission after Final Rejection) (Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the [X]merits; whichever occurs last) under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or [ ] a \$240.00 fee under 37 CFR 1.17(p), or [] (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) under 37 CFR 1.97(d) together with: [ ] a Statement under 37 CFR 1.97(e), as checked below, and [ ] a Petition under 37 CFR 1.97(d)(2), and [] a \$130.00 petition fee set forth in 37 CFR-1.17(i). [ ] (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee) \_be placed in the application filewrapper.

Applicant requests that the attached IDS and cited reference(s)

## Statement Under 37 CFR 1.97(e)

]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
Enclos	ed herewith is form PTO-1449:
[X]	Copies of the cited references are enclosed.
[]	Copies of cited references are enclosed except those entered in prior application, U.S. Serial  No, and references that are not required to be submitted under 37 CFR 1.98.
[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
Conci	se Explanation Requirement (non-English references):
[]	The "concise explanation" requirement for reference(s) under 37 CFR 1.98(a)(3) is satisfied by:
	the explanation provided on the attached sheet.
	[ ] the explanation provided in the Specification.
	[ ] submission of the enclosed International Search Report.
	[ ] the enclosed English language abstract.
It is r	equested that the information disclosed herein be made of record in this application.
Meth	od of payment:
[]	Enclosed is a check in the amount of \$
[]	Please charge Deposit Account 08-0380 in the amount of \$
[]	A copy of this Statement is enclosed.
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.
	Respectfully submitted,
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
	By Anne J. Collins Registration No.: 40,564 Telephone: (781) 861-6240 Facsimile: (781) 861-9540
	22421 4700

Lexington, Massachusetts 02421-4799

Dated: Mac (15, 1999)